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Author summary
During the large Ebola outbreak that affected West Africa in 2014 and 2015, studies were
launched to evaluate potential treatments for the disease. A clinical trial to evaluate the
effectiveness of the antiviral drug favipiravir was conducted in Guinea. This paper
describes the main challenges of the implementation of the trial in the Ebola treatment
center of Gue´cke´dou. Following the principles of the Good Clinical Research Practices, we
explored the aspects of the community’s communication and engagement, ethical con-
duct, trial protocol compliance, informed consent of participants, ongoing benefit/risk
assessment, record keeping, confidentiality of patients and study data, and roles and
responsibilities of the actors involved. We concluded that several challenges have to be
addressed to successfully implement a clinical trial during an international medical emer-
gency but that the potential for collaboration between research teams and humanitarian
organizations needs to be highlighted.
Introduction
The largest and most complex Ebola virus outbreak in history started in Guinea in December
2013 and spread rapidly to neighboring countries in March 2014 [1]. As no effective treatment
existed against Ebola virus disease (EVD), Ebola treatment centers (ETC) were only able to
provide supportive care with case-fatality rates above 50% [2].
In August 2014, the World Health Organization (WHO) convened an advisory panel that
unanimously concluded it would be acceptable to assess potential unregistered interventions
that had shown promising results in preclinical laboratory and animal phases but had not been
fully evaluated in phase I or II trials in humans [3]. Me´decins Sans Frontières (MSF), which
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was extensively involved in frontline care for Ebola patients, the French National Research
Institute for Health and Medical Research (INSERM), and Guinean authorities created a part-
nership to conduct a “proof of concept” study on the efficacy of high-dose favipiravir in reduc-
ing mortality in patients with EVD. Favipiravir, a novel viral RNA polymerase inhibitor
developed by the Japanese company Toyama/Fujifilm, was a prioritized drug on the WHO
expert panel’s list because of its good human safety data and promising results against the
Ebola virus in preclinical studies [4–8]. The multisite JIKI study, named after “hope” in the
Malinke language, was a noncomparative, single-arm, open-label clinical trial [9]. Any patient
aged 1 year or older with laboratory-confirmed EVD was offered the opportunity to participate
in the trial and was asked for informed consent. The European Mobile Laboratory consortium
(EMLAB) performed routine laboratory tests (Ebola virus PCR and biochemistry). The proto-
col of the trial has been described elsewhere [9].
With the recruitment of the first patient in the Gue´cke´dou ETC on December 17, 2014, the
JIKI trial became the first phase II study on EVD ever implemented by a research team in col-
laboration with an international nongovernmental organization. This unique situation was
complicated by the international humanitarian crisis associated with the uncontrolled Ebola
virus epidemic and a vulnerable resource-poor setting of rural Guinea.
This paper is a systematic assessment of the JIKI trial implementation in the field at the
Gue´cke´dou ETC, the first center involved in the study. It does not address the prefield aspects
(methodological choices, writing of the protocol). As all authors of the present paper were
involved in the trial, the assessment may be subjective. Our goal is to offer the scientific and
clinical research communities critical feedback into the issues and challenges of this unique sit-
uation in order to highlight potential problems in future EVD outbreaks.
Issues addressed
We will discuss the issues surrounding the implementation of the JIKI trial in the field in
order to address the interaction between Good Clinical Research Practices [10] and the signifi-
cant practical challenges in this particular context (Table 1).
Communication with the community
Communities from Forested Guinea were known to mistrust government and Western
humanitarian aid agencies, which led to serious security incidents [11]. EVD was still
unknown and many rumors were circulating such as that the disease did not exist; that it had
been introduced purposely to reduce the population; and that ETC patients were experimented
on, killed, or had their organs harvested [12, 13]. Rumors had to be countered, and the mes-
sages to the population on the trial objectives and implementation needed to be comprehen-
sive and adapted to the context to minimize fear and rejection as well as inappropriate
expectations. As the spread of the epidemic was unpredictable and a large region potentially
affected, numerous villages had to be reached in a very short time.
To ensure the community involvement in the trial, local leaders, including women’s organi-
zations, youth groups, religious leaders, and village elders, were invited by the research part-
ners to participate in a Community Advisory Board (CAB). This was headed by the regional
coordinator of the fight against Ebola and specifically created to counsel and support the trial
implementation. During the preparation phase, the CAB discussed the trial protocol and the
communication strategy for the community. Following their recommendations, the focus for
communication was put on providing correct and comprehensive information to patients,
their families, and all 350 MSF staff members, most of whom originated from Gue´cke´dou pre-
fecture, rather than informing entire communities. Anthropologists and key national staff
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collaborated to develop the form and content of the messages, which was tested on various
members of the staff to ensure correct translation into local languages, sensitivity to local cul-
ture, and ease of understanding.
At the same time, a mobile health promotion team addressed rumors in the communities,
countered misconceptions, and answered questions on the trial. They also relayed community
responses to the trial team to modify the messages to patients and their families. For example,
when a rumor arose that 4 EVD survivors treated with favipiravir became “crazy” after return-
ing to their villages, a combined MSF and INSERM team visited the villages and discussed the
issue with the families and the local health authorities.
However, the interventions were limited by the rapid geographical expansion of the epi-
demic. It was not possible to ensure that all villages in the ETC catchment area were included
in the communications. Patients referred from prefectures outside Gue´cke´dou would not have
heard any information about the trial.
Ethical conduct
Research with human subjects must ensure that 3 basic ethical principles are followed: respect
for persons, beneficence, and justice [10, 14, 15]. Favipiravir was already shown to be a promis-
ing drug with the potential to improve EVD prognosis; it was therefore considered acceptable
to evaluate this drug in EVD patients. Given the high mortality in children under 5 years [16,
17] and the fact that Ebola virus often strikes in clusters, including relatives [18], excluding
children would certainly have compromised trial acceptability. Dose-finding or tolerance data
in children were not available. A team of paediatric experts concluded that full maturation of
the enzymes involved in the metabolism of favipiravir was achieved by 12 months. Weight-
Table 1. Key recommendations for a trial implementation in an Ebola outbreak.
Principle Recommendation
Communication with
community
Pretrial recruitment and engagement of community leaders in the trial
planning and launch.
Thoughtful preparation and pretest of messages about the trial.
Ethical conduct Evaluation of the inclusion criteria based on equity and risk/benefit
assessment.
Protocol compliance Consensus among clinicians to adapt previous protocols to standard
operational procedures (SOPs).
Ongoing evaluation of acceptability of changes in patient management to
accomplish with trial protocol.
Informed consent Pretrial assessment of cultural adaptation of informed consent.
Continuous training of specific staff to obtain informed consent.
Local consultation for handling exceptional cases (e.g., unaccompanied
children).
Ongoing benefit/risk
assessment
Interpretation of laboratory results considering Ebola virus disease (EVD)
infectivity.
Daily analysis of mortality data.
Records Innovative management of data recording in the Ebola virus high-risk setting:
installation of a scanner, pictures of files, devices allowing decontamination.
Confidentiality Communication of results as soon as possible to avoid rumors.
Clear and early identification of communication channels with media and
political leaders.
Roles and responsibilities Clear definition of responsibilities and communication channels between all
actors involved in the implementation (the French National Research Institute
for Health and Medical Research [INSERM], Me´decins Sans Frontières
[MSF], Guinean authorities, the European Mobile Laboratory consortium
[EMLAB]).
https://doi.org/10.1371/journal.pntd.0005545.t001
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based doses were chosen based on adult dosages, for which safety data were available [19].
Children under the age of 1 year or weighing less than 10 kg had to be excluded; however, in
practice, this resulted in the exclusion of only 2 infants.
Pregnant women were another particularly vulnerable group. Since no human studies of
favipiravir in pregnancy had ever been performed and embryonic teratogenicity was reported
in mice, no insurance company would cover the risk for pregnancy; thus, pregnant women
had to be excluded from the JIKI trial. Pregnant women, however, had a higher case-fatality
rate compared to nonpregnant women. The vast majority of pregnancies in EVD patients
resulted in miscarriage or intrauterine death, and the few babies born died in a few days [20,
21].
To avoid denying pregnant women access to a potentially beneficial investigational product,
MSF accepted responsibility and liability for the emergency use of favipiravir in this group. A
protocol for monitored emergency use, including informed consent and rigorous data collec-
tion, was submitted for approval to the appropriate ethics committees. Pregnancy testing was
introduced for all women of childbearing age admitted in the ETC.
Nonetheless, a time complication occurred, as the emergency-use protocol for pregnant
women was still under ethics review when the trial started. This did not, however, have any
practical impact, because no pregnant women were admitted in the ETC during the trial
period.
Protocol compliance
The trial’s standard operational procedures (SOPs) had to be incorporated into the MSF Ebola
virus case management protocol without creating any negative impact on patient care or add-
ing extra risks for the staff. To ensure compatibility with the routine management protocols
already in place, the research team wrote the SOPs on site with MSF medical staff. Feasibility
and organizational changes were evaluated before implementation to ensure smooth integra-
tion of the trial into clinical activities.
After trial initiation, the first challenge was related to the study endpoint, which was sur-
vival to day 14. Some patients met MSF’s discharge criteria (negative PCR results after 3 days
without symptoms) before day 14 but still needed monitoring. Thus, a rehabilitation zone was
built so that these patients could move more freely but still remain under surveillance of clini-
cal staff.
The second challenge was the follow-up tests for the trial participants. Routine clinical pro-
cedures called for PCR testing at admission and at the end of symptoms, with no blood collec-
tion between these 2 samples. However, the trial protocol demanded extra sampling at day 2
and day 4, which increased risks for patients and staff. In practice, the additional venous sam-
pling was considered acceptable as it included follow-up biochemical tests, which were benefi-
cial to patient care. Patients were informed of the increased number of blood draws at the time
of informed consent. The volume of each blood collection was limited to a minimum. The
diagnostic laboratory adapted its organization to the new requirements, including new sched-
ules and the incorporation of biochemical testing. The clinical staff was trained to use the bio-
chemistry results in EVD practice. There were, however, some limitations related to these new
procedures. Adding new tests at the laboratory led to some unexpected difficulties. The plat-
form, Abaxis Piccolo Xpress analyzer, was sensitive to heat, and the laboratory did not have a
cooling system. Disinfection of the machine was also a challenge, as the chlorine solution nor-
mally used harmed the electronic components.
The third challenge was the need for early initiation of treatment. As the antiviral medica-
tion was expected to be more effective the earlier in the course of the disease it was started, it
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was crucial to include patients in the trial as soon as possible. Treatment initiation, however,
could only be done after the laboratory confirmed EVD and informed consent was obtained.
This required important changes in the staff shifts to ensure that inclusion could be done as
late as 1:00 AM. Moreover, the samples for PCR testing had to reach the diagnostic lab before
6:00 PM, due to the long process of decontaminating samples and performing the necessary
tests. Consequently, some patients arriving late in the evening, mostly those transferred from
other prefectures, had to wait almost 24 hours before inclusion.
Informed consent
Closely related to the principle of respect for the dignity of participants, an informed consent
had to be obtained from all patients before their inclusion in the trial [10]. During the JIKI
trial, communication with potential participants was complicated by a setting of fear, mistrust,
and the disease itself, as well as by clinical trial illiteracy. As consent was only requested from
laboratory-confirmed Ebola virus patients, it had to be obtained in the ETC high-risk zone
from medical staff wearing full personal protective equipment, which clearly hampered com-
munication and the perception of free choice for the patient.
Some patients could not decide for themselves without extensive family consultation. In
addition, there were no clear legal or traditional rules for ethically obtaining proxy consent for
the inclusion of children or impaired persons who arrived at the ETC without guardians.
Several actions were taken to try to ensure a freely given and culturally adapted informed
consent. Firstly, a multidisciplinary team of medical, health-promotion, psychosocial, anthro-
pological, and research personnel translated the informed consent into comprehensive and
culturally sensitive local languages. Secondly, oral consent was preferred over signed consent
because of cultural acceptability; according to the local psychosocial team, signing a document
while hospitalized was considered as signing a legal will. Therefore, informed oral consent was
signed off by 2 witnesses or by the guardian in the case of minors.
Finally, the Gue´cke´dou CAB was consulted regarding unaccompanied children and advised
to seek special authorization from national authorities. The national coordinator of the fight
against Ebola was contacted and accepted the responsibility for the inclusion of unaccompa-
nied minor children in the trial.
However, despite efforts to explain the protocol in local languages, it was difficult to assess
the amount of information understood by each patient, due to language and cultural barriers
and the clinical status of patients.
Ongoing benefit/risk assessment
In order to assure that the benefits continuously outweighed the potential risks associated with
the investigational drug, strict pharmacovigilance of favipiravir was crucial, as no safety data
were available for the high doses used in the trial. However, due to the severity of EVD and
limited availability of clinical facilities, distinguishing potential adverse effects of the favipiravir
treatment from the signs and symptoms of EVD was challenging.
During and after administration of favipiravir, the patients were closely monitored for any
adverse signs or symptoms not corresponding to typical EVD symptoms, with a focus on those
adverse events previously described in clinical studies with favipiravir for the treatment of
influenza infection. Biochemical tests were used to observe possible liver and kidney damage.
However, at the individual patient level, the interpretation of the causes of deterioration was
still difficult, because some signs and symptoms, such as diarrhea, vomiting, or dizziness,
could be related to either EVD or favipiravir.
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Additionally, mortality data were sent to the Data Safety Monitoring Board (DSMB) on a
daily basis. The protocol included rules that allowed for stopping the trial if interim analysis,
planned after every 20 patients, showed that on-trial mortality did not trend lower than pretrial
mortality.
Records
The quality of the data collection is related to clinical staff qualifications as well as quality of
the recording system. Therefore, medical personnel were trained on specific data-collection
methods. What proved to be more challenging was handling these data. Due to the infection-
control restrictions in the ETC, paper-recorded patient data could not leave the high-risk
zone. To address this problem, case report forms and routine patient documents were scanned
inside the high-risk zone, and the data were sent electronically to both the medical and
research databases. Compared to the pretrial practice of verbal transmission of patient data
between the high- and low-risk zones, this new procedure resulted in fewer transcription mis-
takes and less time for the staff in the high-risk zone.
Confidentiality
The context of the trial, with high social, media, and political pressure, threatened the confi-
dentiality of the study data. The trial was an open-label, single-arm study. After the trial was
launched, most EVD-confirmed patients admitted into the ETC received favipiravir treatment.
This was known by the staff and easy to grasp for the local communities. As the primary study
outcome was mortality, confidentiality in regards to individual patient outcome and the poten-
tial efficacy of the favipiravir treatment was difficult to keep undisclosed to the outside world.
In an attempt to limit the spread of rumors in the local community, regular meetings with the
staff were held to explain the need for prudent interpretation of the observed outcomes and
the importance of confidentiality regarding patients and trial results. The ETC teams and CAB
were the first to be informed of interim and final results.
In February 2014, the trial DSMB and Scientific Advisory Board recommended that the
results of the first interim analysis should be shared with the international scientific commu-
nity. These results suggested good tolerance of the drug and the importance of baseline viral
load as a key stratification factor in further final analysis, but they did not demonstrate the
effectiveness of the drug. However, the research team could not control the interpretation of
these interim results by the media and political leaders. Rumors circulated in the national and
international media about favipiravir efficacy. With decreasing EVD incidence rates in For-
ested Guinea, it became obvious that the initial estimation of the patient cohort size would not
be met. National authorities strongly urged the trial leaders to publicly announce the results
before the trial completion in order to make the drug available in other Guinean ETCs.
Roles and responsibilities
Both MSF and INSERM had little experience in the unique collaboration between a humani-
tarian organization and a typical life-science research institute.
The trial agreement stipulated that INSERM was responsible for compliance with the trial
protocol and the quality of data collection and analysis, while MSF was responsible for patient
management. Communication channels were improved when MSF appointed a research coor-
dinator to coordinate trial preparation and patient care and to ensure full integration of the
research and clinical teams.
Additional trial staff, financed by INSERM, were recruited with the same working contracts
as MSF national staff and trained together with the other ETC staff in the trial SOPs. This
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005545 June 22, 2017 6 / 9
process created a strong team spirit and a feeling of ownership of the project and avoided
dividing the staff into 2 groups with different management and working conditions.
Field logistics were provided by MSF, while INSERM was responsible for official communi-
cations about the trial with the media and the authorities.
Discussion
Implementing a phase II clinical trial during a devastating epidemic in a research-illiterate
environment was full of challenges. Success required cultural sensitivity to build trust within
communities and among patients, inclusion criteria based on equity and a risk/benefit assess-
ment, close collaboration between research and clinical teams, and flexibility to adapt trial
procedures to field constraints. The main pitfalls were related to protocol compliance: the tech-
nical lab problems after the introduction of new tests and the contradiction between study
endpoint and clinical discharge criteria. Confidentiality of trial data was not fully controlled
and required continuous surveillance.
In a context of fear and mistrust of international actors, community engagement was essen-
tial to ensure the appropriate implementation and progression of the trial. A pretrial initiative
to inform and involve community leaders; the development of thoughtful, culturally appropri-
ate messages; and a consensual community strategy were essential aspects of this engagement
that should not be neglected in any Ebola virus trial.
Scientists have argued for [22–25] and against [26–28] the use of randomized controlled tri-
als (RCTs) to evaluate Ebola therapies. Our paper focused on field implementation, but this
was also influenced by the methodological choice of a single-arm design. With patients facing
a high probability of mortality and despite the absence of previous efficacy studies, we believe
that individual interests must prevail over purity of trial methodology. It would have been
unethical and impractical to run an RCT demanding patients to consent to conventional, inef-
fective care when a potentially beneficial treatment was available [26, 27]. It is noteworthy that
virtually all Ebola virus therapy clinical trials have had a single-arm design [28–31]. During the
Ebola outbreak, compassionate use of unapproved treatments was criticized because it did not
systematically contribute to building knowledge about therapeutic efficacy [23, 27]. In the JIKI
trial, the use of favipiravir in pregnant women followed a WHO-recommended protocol for
monitored emergency use [32].
In conclusion, the JIKI trial illustrated how an international research team collaborated
both with a humanitarian medical organization and local researchers to improve scientific
knowledge, create innovative partnerships, promote local capacity building in research, and
help EVD patients. Our observations are context specific but may be useful to understand the
complexity and challenges of establishing research activities during future international medi-
cal emergencies.
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